Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase I/Ib Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors

Werewolf Therapeutics, Inc. announced that the first patient has been dosed in a Phase I/Ib clinical trial evaluating WTX-124, the company’s lead INDUKINETM molecule targeting IL-2 for the treatment of solid tumors.